Inhibition of isoprene biosynthesis pathway enzymes by phosphonates, bisphosphonates, and diphosphates

Journal of Medicinal Chemistry

Volumn 47, Issue 21, 2004, Pages 5149-5158

  Cheng, Feng ^a   Oldfield, Eric ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ARGININE; BISPHOSPHONIC ACID DERIVATIVE; DEOXYXYLULOSE 5 PHOSPHATE; DEOXYXYLULOSE 5 PHOSPHATE REDUCTOISOMERASE; DIMETHYLALLYL DIPHOSPHATE ISOMERASE; FOSMIDOMYCIN; GERANYLTRANSFERASE; ISOMERASE; ISOPENTENYL DIPHOSPHATE; LYSINE; MAGNESIUM; PHOSPHONIC ACID DERIVATIVE; PYROPHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RISEDRONIC ACID; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CONTROLLED STUDY; CRYSTALLOGRAPHY; DRUG CONFORMATION; DRUG SYNTHESIS; ENZYME BINDING; ENZYME INHIBITION; ENZYME SYNTHESIS; ESCHERICHIA COLI; LIGAND BINDING; NONHUMAN; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ALDOSE-KETOSE ISOMERASES; ALGORITHMS; ALKYL AND ARYL TRANSFERASES; BINDING SITES; CARBON-CARBON DOUBLE BOND ISOMERASES; CRYSTALLOGRAPHY, X-RAY; DIPHOSPHONATES; GERANYLTRANSTRANSFERASE; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MULTIENZYME COMPLEXES; ORGANOPHOSPHORUS COMPOUNDS; OXIDOREDUCTASES; PHOSPHONIC ACIDS; POLYISOPRENYL PHOSPHATES; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4744357516     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040036s     Document Type: Article

References (33)

1. Rodan, G. A.; Martin, T. J. Therapeutic approaches to bone diseases. Science 2000, 289, 1508-1514.
2. Miller, P. D. Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis. Expert. Opin. Pharmacother. 2003, 4, 2253-2258.
3. Rodriguez, N.; Bailey, B. N.; Martin, M. B.; Oldfield, E.; Urbina, J. A.; Docampo, R. Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate. J. Infect. Dis. 2002, 186, 138-140.
4. Yardley, V.; Khan, A. A.; Martin, M. B.; Slifer, T. R.; Araujo, F. G.; Moreno, S. N.; Docampo, R.; Croft, S. L.; Oldfield, E. In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob. Agents. Chemother. 2002, 46, 929-931.
5. Das, H.; Wang, L.; Kamath, A.; Bukowski, J. F. Vγ2Vδ2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 2001, 98, 1616-1618.
6. Wilhelm, M.; Kunzmann, V.; Eckstein, S.; Reimer, P.; Weissinger, F.; Ruediger, T.; Tony H. P. γδ cells for immune therapy of patients with lymphoid malignancies. Blood 2003, 102, 200-206.
7. Wang, L.; Kamath, A.; Das, H.; Li, L.; Bukowski, J. F. Antibacterial effect of human Vγ2Vδ2 T cells in vivo. J. Clin. Invest. 2001, 108, 1349-1357.
8. Lu, X. J.; Christensen, D. J.; Poulter, C. D. Isopentenyl-diphosphate isomerase: irreversible inhibition by 3-methyl-3,4-epoxybutyl diphosphate. Biochemistry 1992, 31, 9955-9960.
9. Wouters, J.; Oudjama, Y.; Ghosh, S.; Stalon, V.; Droogmans, L.; Oldfield, E. Structure and mechanism of action of isopentenylpyrophosphate- dimethylallylpyrophosphate isomerase. J. Am. Chem. Soc. 2003, 125, 3198-3199.
10. Wouters, J.; Oudjama, Y.; Barkley, S. J.; Tricot, C.; Stalon, V.; Droogmans, L.; Poulter, C. D. Catalytic mechanism of Escherichia coli isopentenyl diphosphate isomerase involves Cys-67, Glu-116, and Tyr-104 as suggested by crystal structures of complexes with transition state analogues and irreversible inhibitors. J. Biol. Chem. 2003, 278, 11903-11908.
11. Jomaa, H.; Wiesner, J.; Sanderbrand, S.; Altincicek, B.; Weidemeyer, C.; Hintz, M.; Turbachova, I.; Eberl, M.; Zeidler, J.; Lichtenthaler, H. K.; Soldati, D.; Beck, E. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science 1999, 285, 1573-1576.
12. Wiesner, J.; Borrmann, S.; and Jomaa, H. Fosmidomycin for the treatment of malaria. Parasitol. Res. 2003, 90, S71-S76.
13. Tarshis, L. C.; Proteau, P. J.; Kellogg, B. A.; Sacchettini, J. C.; Poulter, C. D. Regulation of product chain length by isoprenyl diphosphate synthases. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 15018-15023.
14. Steinbacher, S.; Kaiser, J.; Eisenreich, W.; Huber, R.; Bacher, A.; Rohdich, F. Structural basis of fosmidomycin action revealed by the complex with 2-C-methyl-D-erythritol 4-phosphate synthase (IspC). Implications for the catalytic mechanism and anti-malaria drug development. J. Biol. Chem. 2003, 278, 18401-18407.
15. Hosfield, D. J.; Zhang, Y.; Dougan, D. R.; Broun, A.; Tari, L. W.; Swanson, R. V.; Finn, J. Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis. J. Biol. Chem. 2004, 279, 8526-8529.
16. Goodsell, D. S.; Morris, G. M.; Olson, A. J. Automated docking of flexible ligands: applications of AutoDock. J. Mol. Recognit. 1996, 9, 1-5.
17. SYBYL 6.9, Tripos Inc., 1699 South Hanley Rd., St. Louis, MO 63144.
18. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, Jr., K. M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
19. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity - A rapid access to atomic charges. Tetrahedron 1980, 36, 3219-3288.
20. Clark, M.; Cramer, R. D., III.; Van Opdenbosch, N. Validation of the general purpose Tripos 5.2 force field. J. Comput. Chem. 1989, 10, 982.
21. PDB File 1PPW: Wouters, J.; Yin, F.; Song, Y.; Oudjama, Y.; Stalon, V.; Droogmans, L.; Kuzuyama, T.; Monta, C. T.; Oldfield, E., unpublished results.
22. Yajima, S.; Nonaka, T.; Kuzuyama, T.; Seto, H.; Ohsawa, K. Crystal structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase complexed with cofactors: implications of a flexible loop movement upon substrate binding. J. Biochem. 2002, 131, 313-317
23. Wallace, A. C.; Laskowski, R. A.; Thornton, J. M. LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995, 8, 127-134.
24. Dunford, J. E.; Thompson, K.; Coxon, F. P.; Luckman, S. P.; Hahn, F. M.; Poulter, C. D.; Ebetino, F. H.; Rogers, M. J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 2001, 296, 235-242.
25. Montalvetti, A.; Bailey, B. N.; Martin, M. B.; Severin, G. W.; Oldfield, E.; Docampo, R. Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J. Biol. Chem. 2001, 276, 33930-33937.
26. Montalvetti, A.; Fernandez, A.; Sanders, J. M.; Ghosh, S.; Van Brussel, E.; Oldfield, E.; Docampo, R. Farnesyl pyrophosphate synthase is an essential enzyme in Trypanosoma brucei. In vitro RNA interference and in vivo inhibition studies. J. Biol. Chem. 2003, 278, 17075-17083.
27. Sanders, J. M.; Gomez, A. O.; Mao, J.; Meints, G. A.; Van Brussel, E. M.; Burzynska, A.; Kafarski, P.; Gonzalez-Pacanowska, D.; Oldfield, E. 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates. J. Med. Chem. 2003, 46, 5171-5183.
28. Keller, R. K.; Fliesler, S. J. Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of the isoprenoid pathway. Biochem. Biophys. Res. Commun. 1999, 266, 560-563.
29. Martin, M. B.; Sanders, J. M.; Kendrick, H.; de Luca-Fradley, K.; Lewis, J. C.; Grimley, J. S.; Van Brussel, E. M.; Olsen, J. R.; Meints, G. A.; Burzynska, A.; Kafarski, P.; Croft, S. L.; Oldfield, E. Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J. Med. Chem. 2002, 45, 2904-2914.
30. Kotsikorou, E.; Oldfield, E. A quantitative structure-activity relationship and pharmacophore modeling investigation of aryl-X and heterocyclic bisphosphonates as bone resorption agents. J. Med. Chem. 2003, 46, 2932-2944.
31. Sanders, J. M.; Ghosh, S.; Chan, J. M. W.; Meints, G.; Wang, H.; Raker, A. M.; Song, Y.; Colantino, A.; Burzynska, A.; Kafarski, P.; Monta, C. T.; Oldfield, E. Quantitative structure-activity relationships for γδ T cell activation by bisphosphonates. J. Med. Chem. 2004, 47, 375-384.
32. Gossman, W. L.; Wilson, S. R.; Oldfield, E. Three hydrates of the bisphosphonate risedronate, consisting of one molecular and two ionic structures. Acta Crystallogr. C 2003, 59, m33-m36.
33. Martin, M. B.; Arnold, W.; Heath, H. T., III.; Urbina, J. A.; Oldfield, E. Nitrogen-containing bisphosphonates as carbocation transition state analogues for isoprenoid biosynthesis. Biochem. Biophys. Res. Commun. 1999, 263, 754-758.